Drugs, QTc Interval Prolongation and Final ICH E14 Guideline
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 28 (11), 1009-1028
- https://doi.org/10.2165/00002018-200528110-00003
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Modeling and Interpreting QTc Prolongation in Clinical Pharmacology StudiesDrug Information Journal, 2005
- The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT IntervalJournal of the American College of Cardiology, 2005
- Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic ActivityMolecular Pharmacology, 2005
- Genetic susceptibility to acquired long QT syndrome: Pharmacologic challenge in first-degree relativesHeart Rhythm, 2005
- Pentamidine-Induced Long QT Syndrome and Block of hERG TraffickingThe Journal of pharmacology and experimental therapeutics, 2004
- Mechanisms of Arsenic-Induced Prolongation of Cardiac RepolarizationMolecular Pharmacology, 2004
- Comparing Methods of Measurement for Detecting Drug‐Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG StudiesAnnals of Noninvasive Electrocardiology, 2004
- Ethnic Differences in Cardiac Potassium Channel Variants: Implications for Genetic Susceptibility to Sudden Cardiac Death and Genetic Testing for Congenital Long QT SyndromeMayo Clinic Proceedings, 2003
- Torsade de pointes in a patient receiving intravenous vasopressinCritical Care Medicine, 1988
- Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmiasThe American Journal of Cardiology, 1987